Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

Recruiting now

Conditions studied: Cerebral Hemorrhage, Acute Lobar Haematoma

In brief

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced MRI. By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.

Key facts

Study ID

NCT06781034

Run by

Centre Hospitalier Universitaire de Nīmes

People needed

128

Starts

2025-02-03

Expected to finish

2026-12-01

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;
• Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.

You may not qualify if…

• Patient refusing to participate

Where it is running

• CHU de Nîmes — Nîmes, Gard, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.